Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TEMtoGo: Temocillin vs Ceftriaxone for Neisseria Gonorrhoeae Infections
NCT07631364Phase 3Not yet recruiting
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Sep 2026
- Primary completion
- Oct 2028
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of temocillin in Gonorrhea (3 arms), sponsored by Assistance publique - Hôpitaux de Paris. Primary endpoint: Proportion of participants with a negative PCR for NG at urine/vagina site at Day 21. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
temocillin
03
Conditions
Gonorrhea
Beyond the preview
Go deeper on NCT07631364.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07631364.